Beta Bionics and the promise of autonomy
A simpler diabetes tech is in the offing, but some patients are yet to be convinced that a device knows best.
Astra puts a bet on gene editing
Logicbio gives Astra a novel gene-editing technology at a bargain price.
Full steam ahead at F2G
The UK developer has the launch of what could be the first in a new class of antifungals in its sights.
Pepgen aims to overtake Sarepta
Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.
T3D puts a bet on Alzheibetes
An unusual update at last month’s AAIC meeting puts the focus on a phase 2 readout next year, but time might be running out.
Novo’s cardiovascular and rare disease charge continues
Before the Forma deal Novo brought in assets via Corvidia, Prothena and Heartseed. Some have progressed faster than others.
Ovid takes a novel approach to gene therapy
Ovid and its partner Gensaic have high hopes for a brand-new delivery method, and much to prove.
Better Therapeutics banks on data and partnerships
But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.
Delfi aims for a cheaper liquid biopsy
With a fresh $225m in the bank, Delfi works towards a cut-price, next-generation lung cancer screen.
